We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Microtubule disruption reduces metastasis more effectively than primary tumor growth.
- Authors
Thompson, Keyata N.; Ju, Julia A.; Ory, Eleanor C.; Pratt, Stephen J. P.; Lee, Rachel M.; Mathias, Trevor J.; Chang, Katarina T.; Lee, Cornell J.; Goloubeva, Olga G.; Bailey, Patrick C.; Chakrabarti, Kristi R.; Jewell, Christopher M.; Vitolo, Michele I.; Martin, Stuart S.
- Abstract
Clinical cancer imaging focuses on tumor growth rather than metastatic phenotypes. The microtubule-depolymerizing drug, Vinorelbine, reduced the metastatic phenotypes of microtentacles, reattachment and tumor cell clustering more than tumor cell viability. Treating mice with Vinorelbine for only 24 h had no significant effect on primary tumor survival, but median metastatic tumor survival was extended from 8 to 30 weeks. Microtentacle inhibition by Vinorelbine was also detectable within 1 h, using tumor cells isolated from blood samples. As few as 11 tumor cells were sufficient to yield 90% power to detect this 1 h Vinorelbine drug response, demonstrating feasibility with the small number of tumor cells available from patient biopsies. This study establishes a proof-of-concept that targeted microtubule disruption can selectively inhibit metastasis and reveals that existing FDA-approved therapies could have anti-metastatic actions that are currently overlooked when focusing exclusively on tumor growth.
- Subjects
UNITED States. Food &; Drug Administration; TUMOR growth; MICROTUBULES; METASTASIS; CELL survival; VINORELBINE; DRUG approval; PILOT projects; BIOPSY; ANIMAL experimentation; ANTINEOPLASTIC agents; BLOOD collection; DESCRIPTIVE statistics; TUMORS; CELL lines; CYTOPLASM; PHENOTYPES; PHARMACODYNAMICS
- Publication
Breast Cancer Research, 2022, Vol 24, Issue 1, p1
- ISSN
1465-5411
- Publication type
journal article
- DOI
10.1186/s13058-022-01506-2